A report by A World Health Organization (WHO) has found that there are no negative health risks or outcomes, but rather, applications for cannabidoil (CBD). According to the report, WHO stated that CBD is safe for human (and animal) consumption and is not correlated with any negative health effects, despite the U.S. federal policy on the cannabinoid chemical.
Experts on the subject said that CBD (a non-psychoactive component found in cannabis) has no abuse potential, for it does not instigate physical dependence. CBD, unlike THC, does not give consumers the feeling of being high or stoned.
“To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD,” they wrote. Actually, evidence suggests the CBD eases the effects of THC (whether anxious or blissful), according to this and other similar reports.
The WHO team also concluded that CBD was an effective treatment for epilepsy in adults, children, and even animals. There is also prior evidence that suggests CBD can be useful in treating those with Alzheimer’s disease, psychosis, cancer, Parkinson’s disease, and other serious conditions.
In response to these similar discoveries in recent years, several countries have reevaluated and modified their national controls to contain CBD as a medicinal product. But the U.S. isn’t among them. In the United States, CBD remains classified as a Schedule I controlled substance, meaning it has a “high potential for abuse” in the federal government’s eyes. However, the “unsanctioned medical use” of CBD is quite common.
Even though CBD itself is safe, the industry researchers have warned that not all CBD products are created equally, purely, or with the same methods of extraction. And while reports of negative reactions to CBD are few and far between, experts say that cannabinoid isn’t entirely to blame. Reported adverse effects may be a result of drug-drug interactions between the patients’ existing medications.
The Food and Drug Administration (FDA) has repeatedly refused to update the position on cannabis products against a large and growing body of evidence on the subject, including WHO and it’s final review of CBD.
Hopefully, this time the FDA will listen to the findings and learn something.